Lloyd Central Compounding Pharmacy (Portland Compounding Pharmacy, LLC), Portland, OR

Is Lloyd Central Compounding Pharmacy (Portland Compounding Pharmacy, LLC) registered with the FDA as a 503B outsourcing facility?

No matching record found in FDA’s registered outsourcing facility list (updated Nov 6, 2026) on Nov 15, 2026, searching by name and location. FDA’s compounding inspections and actions page labels it a 503A facility.

Does Lloyd Central Compounding Pharmacy (Portland Compounding Pharmacy, LLC) hold a Oregon pharmacy license?

State board of pharmacy records for Oregon are not checked: the board lists 2025 and 2026 actions in a script-driven table and older actions only on request, and its license lookup is an interactive search.

Has Lloyd Central Compounding Pharmacy (Portland Compounding Pharmacy, LLC) had a state board action or FDA letter?

FDA letters: record found. FDA’s compounding inspections and actions page, current as of Oct 22, 2026, lists 1 state referral letter (Apr 7, 2020) and 1 FMD-145 letter (Apr 7, 2020) for Lloyd Central Compounding Pharmacy (Portland Compounding Pharmacy, LLC). State board of pharmacy records for Oregon are not checked: the board lists 2025 and 2026 actions in a script-driven table and older actions only on request, and its license lookup is an interactive search. The state referral and handoff letters above are FDA’s letters to the state, not board actions.

FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.

Names in FDA records
Portland Compounding Pharmacy, LLC; Lloyd Central Compounding Pharmacy
Location
Portland, OR
Type as FDA labels it
503A
FDA 503B list
No matching record found
Form 483s on FDA’s actions page
1
Warning letters on FDA’s actions page
0
Latest action on that page
Apr 7, 2020
FDA Data Dashboard inspections
1 inspection: 1 VAI; 1 published Form 483
Form 483 text on this page
1 Form 483, 3 observations
State board records
Not checked

FDA inspections and letters

FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as Portland Compounding Pharmacy, LLC, (dba Lloyd Central Compounding Pharmacy), a 503A facility, with 3 dated actions.

Document
Apr 7, 2020State referral letterState Referral Letter Issued 04/07/2020Not linked by FDA
Apr 7, 2020FMD-145 letterFMD-145 Letter Issued 04/07/2020FDA copy (archived)
Nov 26, 2019Form 483483 Issued 11/26/2019FDA copy (archived)

A Form 483 lists investigator observations, not a final FDA determination. An untitled or FMD-145 letter states FDA’s view when it was issued.

FDA inspection classifications and published Form 483s

The FDA Data Dashboard, read Nov 15, 2026, lists Portland Compounding Pharmacy LLC, Portland, OR (FEI number 3015762738), matched to this page by exact name, city and state. It lists 1 inspection: 1 VAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.

Inspection endedClassificationProject area and product typeFEIInspection ID
Nov 26, 2019Voluntary Action Indicated (VAI)Drug Quality Assurance (Drugs)30157627381111227

Form 483s FDA has published for this site

FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.

Form 483 observations

A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.

FDA’s published Form 483 for this site has 3 numbered observations in all. Each observation is quoted from the PDF as FDA numbered it. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.

Inspection dated Nov 26, 2019 by FDA (dates on the form not read): 3 observations

Firm on the cover
· Lloyd Central Compotwding Pharmacy l, 2606 NE Broadway St Ste B ', Portland OR 97232-1898 I
FEI number
3015762738
Establishment type on the cover
Producer of Sterile and Non-Sterile Drugs ~ THIS DOCUMENT LISTS OBSERVATIONS MADE BY THE FDA REPRESENTATIVE(S) DURING THE INSPECTION OF YOUR FACILITY. THEY ARE INSPECTIONAL OBSERVATIONS; AND DO NOT REPRESENT A FINAL AGENCY DETERMINATION REGARDING YOUR COMPLIANCE. IF YOU HAVE AN OBJECTION REGARDING AN I OBSERVATION., OR HAVE IMPLEMENTED, OR PLAN TO IMPLEMENT CORRECTIVE ACTION IN RESPONSE TO AN OBSERVATION, YOU MAY DISCUSS THE OBJECTION OR ACTION WITH THE FDA REPRESENTATIVE(S) DURING THE INSPECTION OR SUBMIT THIS INFORMATION TO FDA AT THE ADDRESS ABOVE IF YOIJ HAVE ANY QUESTIONS, PLEASE CONTACT FDA AT THE PHONE NUMBER AND ADDRESS ABOVE
FDA district office on the cover
22215 26th Ave SE Suite 210 Bothell, WA 98021
Matched to this page by
FEI number on the cover; linked from actions page, Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

Observation 1

~ I I

Disinfecting agents and cleaning wipes used in the ISO 5 classified aseptic processing areas were not sterile.

Specifically,

On 11/13/2019 during the production of Hydromorphone HCL 20MG/ML Intrathecal, Lot#: 374767> we observed the use of non-sterile wipes <Redacted B4> to introduce supplies into the ISO 5 classified area.

ln addition <Redacted B4> a non-sterile disinfectant, is used inside the ISO 5 classified area on a regular basis <Redacted B4> cleaning purposes.

I

Observation 2

You produced hazardous drugs without providing adequate cleaning of work surfaces and cleaning of utensils to prevent cross-contamination.

Specifically,

Your firm currently produces testosterone and estrogen products without adequate cleaning to deactivate any hazardous drug residues. You firm currently uses store bought soap and water only for these product utensils and work surfaces. A strong oxidizer for deactivation of said residues is used.

Observation 3

Fach batch of drug product purporting to be pyrogen-free is not laboratory tested to determine conformance w such requirements.

Specifically, not all batches of sterile drug products prepared by your firm were tested for endotoxin before release. For example,

l l. Hydromorphone HCL/Clonidine HCL 5MG/60MCG/ML Intrarhecal, Lot#: 356530; Rx <Redacted B4>:

b 6 2. Hydromorphone HCL 7.SMG/ML lntrathecal, Lot#: 359865; Rx:

j i I

I

i !

(. I l I

t

State board of pharmacy records

State board of pharmacy records for Oregon are not checked: the board lists 2025 and 2026 actions in a script-driven table and older actions only on request, and its license lookup is an interactive search.

This page restates FDA’s lists. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.